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Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in west-
ern countries. Considering the increasing incidence and prevalence of this condition, it is
highly relevant to better characterise these patients in Portugal, where data is still scarce.
Methods
To determine incidence, clinical presentation, survival and second malignancies, a popula-
tion-based historical cohort study was conducted. Cases of interest were identified through
the South Region Cancer Registry database and additional data sources. Patients aged
�18 years, with a confirmed diagnosis of CLL or small lymphocytic lymphoma between Jan-
uary 1st, 2013 and December 31st, 2014 were included. Patients were followed-up until
death or cut-off date (December 31st, 2019).
Results
A total of 496 patients were included and median follow-up time was 5.46 years. Crude inci-
dence rates were 5.03 and 5.22 per 100,000 inhabitants for 2013 and 2014, respectively,
and age-adjusted incidence rates were 3.18:100,000 European population for 2013 and
3.35:100,000 European population for 2014. Median age at diagnosis was 71 years and the
male/female ratio was 1.40. The majority of patients had leukemic presentation of the dis-
ease (86.09%), was diagnosed in Binet stage A (75.58%) and did not present B symptoms
(84.01%), anaemia (haemoglobin�10g/dL; 90.63%) nor thrombocytopenia (platelet count
�100 000/μL; 91.73%). Five-year overall survival (OS) rate was 70.53% (95%CI 66.31–
74.34) and age, lactate dehydrogenase, Binet stage and a�5 Charlson comorbidity index
score were independently associated with OS. Standardised-incidence ratios for any sec-
ond malignancy and cutaneous squamous cell carcinoma were 1.59 (95%CI 1.19–2.08)
and 10.15 (95%CI 6.28–15.51), respectively.
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Conclusion
Incidence, clinical presentation and survival of CLL Portuguese patients are similar to those
reported for other western countries. The increased risk of second malignancies raises con-
cerns and needs adequate clinical watchfulness.
Introduction
Chronic lymphocytic leukaemia (CLL) is an indolent lymphoproliferative malignancy of
CD5+ mature B cells involving peripheral blood, bone marrow and lymphoid organs. It is the
most common leukaemia among adults in western countries, with incidence rates ranging
between 4 and 6 per 100,000 people per year; in contrast, it is rare in Asia, particularly in Japan
and Korea. Incidence increases with age, to more than 30:100,000 inhabitants per year at an
age of>80 and, at diagnosis, at least 70% of patients are older than 65 years [1–4].
The diagnosis requires a minimum of 5000 B lymphocytes/μL in the peripheral blood and
its clonality needs to be confirmed by flow cytometry [5–7]. Additionally, small lymphocytic
lymphoma (SLL) represents a different clinical presentation of the same disease and follows
the same management guidelines [3]. This entity is characterised by the presence of lymphade-
nopathy and/or organomegaly with less than 5000 B lymphocytes/μL in the peripheral blood
with a CLL phenotype [5–7].
CLL course is extremely heterogeneous. At diagnosis, the majority of patients are asymp-
tomatic and the disease is detected in a routine blood count. In advanced stages, patients may
present anaemia and thrombocytopenia and, scarcely ever, B symptoms. To better stratify
patient’s death risk, numerous clinical and biological prognostic predictors have been identi-
fied, including Rai and Binet staging systems [8,9], lactate dehydrogenase and β2-microglobu-
lin serum levels [10], tumour genomic aberrations [del(11q), del(13q), del(17p), 12 trisomy)]
[11], the mutational status of the immunoglobulin heavy-chain variable region genes (IGHV)
[12,13], protein expression (CD38, ZAP-70) [12,14], and the mutational status of the TP53
tumour-suppressor gene [15]. The CLL international prognostic index (CLL-IPI) includes
some of these variables and has been validated as predictive of clinical outcomes in various set-
tings in the era of immunochemmotherapy [16].
As other indolent lymphoid disorders, CLL has favourable survival results, with a 5-year rel-
ative survival of 80–86% and a death rate of 1.1 per 100,000 people per year [4,17], despite the
fact that these patients have an increased risk of developing second malignancies [18,19].
The increasing incidence and prevalence of CLL has augmented the impact of this condi-
tion globally. Therefore, it is exceptionally relevant to better understand epidemiology and
patients’ characteristics in order to adequate health, social and public health interventions, par-
ticularly in Portugal, where this data is still scarce. The aim of this study was to determine the
incidence, clinical presentation at diagnosis, survival and occurrence of second malignancies
in CLL recurring to a diagnosis cohort from the south region of Portugal.
Material and methods
Study design
A population-based historical cohort study was conducted and is reported in accordance with
STROBE statement [20].
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Data sources and ethics
The South Region Cancer Registry (ROR-Sul), established in Portugal in 1988, is a population-
based cancer registry covering 4.8 million inhabitants from the regions of Lisboa e Vale do
Tejo, Alentejo, Algarve and autonomous region of Madeira. ROR-Sul’s database complies with
international recommendations stated by the International Agency for Research on Cancer
[21] and collects relevant information from time of cancer diagnosis until death. Cancer cases
are signalised through institution-based databases (mainly from pathology departments) and
numerous variables are semi-automatically transferred into the database (e.g. date of birth,
sex, place of residence, topography, morphology, vital status and date of death). Other relevant
information, mainly data related to disease stage, prognostic features and treatments are regis-
tered manually by trained and experienced personnel at each health institution. The current
study was conducted recurring to ROR-Sul’s database.
This study was approved by the Instituto Português de Oncologia de Lisboa Francisco Gentil
Ethics Committee on September 6th, 2018 (reference: UIC/1201). Informed consent was not
required because this is a historical cohort study, all variables used in this study are already
part of the ROR-SUL database and are specifically collected to accomplish registry purposes,
as dictated by National law.
Study population
Patients aged 18 years or older diagnosed with CLL or SLL (morphology codes: M9670/3 and
M9823/3) [22] between January 1st, 2013 and December 31st, 2014 were included. Cases with-
out histological or immunophenotypical confirmation were excluded. Cases exhaustiveness
was maximized per two independent strategies: (a) cases registered in ROR-Sul database with
a diagnosis in the study period of non-otherwise specified lymphomas and leukaemias were
centrally reviewed and cases of interest were recoded (b) flow cytometry laboratories from
public and private hospitals provided results from immunophenotypic analysis conducted
during the study period and additional cases of interest were registered in ROR-Sul’s database.
Patients were followed-up between diagnosis and death or cut-off date (December 31st, 2019).
Information of interest included: age, sex, date of diagnosis, morphology, comorbidities
(according to the Charlson index), leukocyte, lymphocyte and platelet counts, haemoglobin, B
symptoms, Eastern Cooperative Oncology Group Performance Status (ECOG PS), lactate
dehydrogenase, β2-microglobulin, Rai stage, Binet stage, del(17p), del(11q), del(13q), trisomy
12, TP53 mutations, IGHV mutational status, treatment realisation and type of first line treat-
ment, topography and morphology of second malignancies, vital status and date of death/last
known contact. Data for variables of interest was centrally validated by the research team.
Study outcomes
Incidence was determined recurring to crude and age-adjusted (European population) rates.
Demographic and clinical characterization was conducted considering information available
at diagnosis. Morphology was coded considering a lymphocyte cut-off of 5000x106/L, accord-
ing to WHO classification [5–7] Comorbidities were collected considering those included in
the Charlson comorbidity index (CCI) [23]. Characterisation of chromosomal aberrations per
fluorescence in situ hybridization (FISH) and mutational status of the IGHV and TP53 were
conducted considering the evaluations performed before the initiation of first treatment.
Overall survival was defined as the time elapsed between diagnosis and death due to any
cause. The second malignancies considered were those occurring at least 6 months after CLL/
SLL diagnosis (in order to exclude synchronous neoplasms) [24] and included all malignant
tumours except basal cell carcinomas.
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Statistical analysis
Data was analysed in a pseudonymized format. Crude incidence rates were computed for the
years of 2013 and 2014 using the direct method and considering the resident population in
ROR-Sul coverage area publicly provided by Statistics Portugal (INE) [25]. Additionally, age-
standardised incidence rates were computed for the European standard population [26].
Demographic and clinical characteristics and second malignancies were summarised using
absolute and relative frequencies for categorical variables and median and interquartile ranges
(IQR) for continuous variables. We established a cut-off of 20% for missing data and, when
the unknown information was lower than the cut-off, it was presented as a complete-case anal-
ysis. Otherwise, it was computed for the study population [27]. CCI was calculated according
to the original method and summarised with frequencies, mean and standard deviation. Post-
hoc bivariate analysis relating Binet stage with sex and age (<65 and�65 years) were per-
formed using chi-square test.
Kaplan-Meier estimates were used to compute OS and patients without the event of interest
were censored at cut-off date. 5-year survival rates were calculated considering a 95% confi-
dence interval (CI). The log-rank test was used to compare differences between strata. Post-
hoc subgroup analyses for OS according to age (<65 and�65 years) were performed.
A multivariable proportional hazard regression was used to evaluate the association
between variables of interest and OS. Covariates with more than 30% of unknown data were
not considered for modeling. Variables included in the multivariable regression were the sig-
nificant covariates in univariate analysis (cut-off p<0.20) or clinically relevant based on their
known prognostic value. Assumptions of the model were verified.
Standardised incidence ratio (SIR) was calculated as the ratio between observed and
expected number of second primary malignancies. The expected number of cancers was com-
puted by multiplying ROR-Sul crude incidence rates for 2013 stratified by sex and age groups
by stratum-specific person-years at risk of the CLL cohort and summing across strata. For
each cancer type, SIR was not calculated to those with less or equal to 5 observed cases. 95%CI
was calculated assuming a Poisson distribution for the observed cases.
All statistical analyses were performed using the software Stata version 13.0 [28].
Results
We first identified in ROR-Sul database 401 cases that met the inclusion criteria. Posteriorly,
126 additional cases were identified through the flow cytometry laboratories’ results and, lastly,
31 cases were excluded as they met the exclusion criteria. The final number of patients
included in the study was 496 (Fig 1). Median follow-up of the study population was 5.46
years; only 2 patients (0.40%) were lost to follow-up.
Incidence and clinical presentation
Crude incidence rates were determined to be 5.03 and 5.22 per 100,000 inhabitants for 2013
and 2014, respectively. Age-adjusted incidence rates (European population), were 3.18:100,000
people for 2013 and 3.35:100,000 people for 2014.
Clinical presentation at diagnosis is shown in Table 1. Median age at diagnosis was 71
years, with 70.77% of patients older than 65 years, and the sex distribution (male/female ratio)
was 1.40. The majority of patients had a leukemic picture (80.04%) and were diagnosed in
Binet stage A (75.85%). Male sex was associated with more advanced Binet stages (p = 0.044);
no statistical significant relationships were found between age and stage (p = 0.290).
At least one chromosomal aberration was evaluated by FISH in 203 patients (40.93%) and
the four abnormalities of interest were studied in 198 patients (39.92%). Of these, 62.12%
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exhibited abnormalities and the most prevalent alteration was 13q deletion (Table 2). In 104
patients there was one aberration, 12 patients had two and 3 patients had three aberrations.
The mutational status of the IGHV and TP53 were evaluated in 82 (16.53%) and 39 (7.86%)
patients, respectively. With respect to IGHV, 43 patients (52.44%) were hypermutated and 39
(47.56%) were non-hypermutated. TP53 mutation was present in 5.13% of evaluated patients.
Treatment and survival
During the study period, the majority of patients did not receive any treatment (mostly due to
a watch and wait strategy) and 188 patients (37.90%) received at least one therapeutic line for
CLL. The most common first-line treatment options were chemmoimmunotherapy (46.28%),
including fludarabine, cyclophosphamide, rituximab (n = 49; 26.06%) and bendamustine,
rituximab (n = 14; 7.45%), alkylating agent +/- corticosteroids (28.19%) and anthracycline or
vinca alkaloids-containing regimens (17.02%).
OS estimate is presented in Fig 2. Median OS was not reached and 5-year survival rate was
70.53% (IC95% 66.31–74.34).
OS estimate was stratified according to Binet and Rai staging systems (S1 and S2 Figs).
Median OS was not reached for the majority of strata although it was reached for high-risk/
advanced stages [Binet C: 1.62 years (0.63-not reached); Rai III/IV: 1.62 years (0.64-not
reached)]. Additionally, OS was stratified according to age (<65 and�65) and, although
medians were not reached, the 5-year OS rates were 86.66% (95%CI 83.43–93.63) and 62.62%
(95%CI 57.33–67.45) for younger and older patients, respectively.
Univariate and multivariable analysis evaluating the association between baseline character-
istics and OS is presented in Table 3. Due to the high number of cases with missing informa-
tion, β2-microglobulin levels were not included in this analysis. Age, lactate dehydrogenase,
Fig 1. Flowchart for the identification of CLL/SLL cases diagnosed in 2013–2014 in ROR-Sul coverage area.
https://doi.org/10.1371/journal.pone.0258423.g001
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Table 1. Baseline characteristics of CLL patients diagnosed in 2013–2014 in ROR-Sul coverage area.
Characteristics n = 496
Age
Median (IQR) 71 (62–78)






Small lymphocytic lymphoma 99 (19.96)
B-cell chronic lymphocytic leukaemia 397 (80.04)





Mean (SD) 0.87 (1.24)
0, n (%) 265 (53.43)
1–2, n (%) 189 (38.10)
3–4, n (%) 32 (6.45)
�5, n (%) 10 (2.02)
Unknown, n (%) 0 (0.00)
Leukocyte count (/μL)
Median |(IQR) 16550 (11600–24100)
Unknown, n (%) 31 (6.25)
Lymphocyte count (/μL)
Median (IQR) 10962.5 (6350–18390)
Unknown, n (%) 34 (6.85)
Haemoglobin (g/dL)
Median (IQR) 13 (12–15)
�10 g/dL, n (%) 43 of 459 (9.37)
Unknown, n (%) 37 (7.46)
Platelet count (/μL)
Median (IQR) 191000 (149000–234000)
�100 000/μL, n (%) 29 of 455 (6.37)
Unknown, n (%) 41 (8.27)
Lactate dehydrogenase, n (%)
Normal 242 (48.79)
Elevated 121 (24.40)




Unknown/not evaluated 278 (56.05)
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Binet stage and a CCI�5 score were identified as independent factors associated with OS
(p<0.001, p = 0.004, p = 0.002 and p = 0.021, respectively).
Second malignancies
A total of 53 second malignant tumours were identified in 46 patients, which corresponds to a
cumulative incidence of 10.69%. The most common second malignancies were cutaneous
squamous cell carcinoma (CSCC) (n = 21), prostate cancer (n = 5) and malignant tumours of
the central nervous system (n = 4) (S1 Table). The risk of any second primary cancer in CLL
patients was increased comparing to the general population [SIR = 1.59 (95%CI 1.19–2.08)].
Site-specific SIR was calculated to CSCC and estimated to be 10.15 (95%CI 6.28–15.51).
Discussion
Cancer registries are important tools in the generation of epidemiological data. To the best of
our knowledge, this is the first population-based study that aimed to characterise the inci-
dence, clinical presentation, survival and the occurrence of second malignancies in CLL
patients in Portugal. As this condition is particularly incident and prevalent in western coun-
tries, with a significant impact on both social and health systems, it is of utmost relevance to
better understand its epidemiology and patients’ characteristics.
With respect to cases completeness, it is worth noticing that, in this study, patients identi-
fied through flow cytometry laboratories represent over 25% of the total cases; in fact, a
Table 1. (Continued)
Characteristics n = 496
Rai stage, n (%)
0 199 of 472 (42.16)
I/II 230 of 472 (48.73)
III/IV 43 of 472 (9.11)
Unknown 24 (4.84)
Binet stage, n (%)
A 358 of 472 (75.85)
B 73 of 472 (15.47)
C 41 of 472 (8.69)
Unknown 24 (4.84)
CCI, Charlson comorbidities index; IQR, interquartile range; M, male; F, female.
https://doi.org/10.1371/journal.pone.0258423.t001
Table 2. Prevalence of chromosomal aberrations on CLL patients detected by FISH.
Aberration n = 496
Not evaluated 293 (59.07%)
Evaluated 203 (40.93%)
No abnormalities 75 of 198 (37.88%)
Chromosomal abnormalities 123 of 198 (62.12%)
Del(13q) 68 of 199 (34.17%)
Trisomy 12 42 of 200 (21.00%)
Del(11q) 22 of 198 (11.11%)
Del(17p) 16 of 199 (8.04%)
https://doi.org/10.1371/journal.pone.0258423.t002
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20–30% under-reporting of CLL cases for other population-based cancer registries was already
described [29–31]. Thus, the use of additional information sources as a routine strategy is
mandatory in order to provide accurate incidence and survival data for CLL/SLL.
Fig 2. Kaplan-Meier estimate for OS.
https://doi.org/10.1371/journal.pone.0258423.g002
Table 3. Association between baseline characteristics and OS in CLL patients.
Baseline characteristic Events Univariate analysis Crude HR
(95%CI)
p-value Multivariable analysis Adjusted HR (95%CI) n = 343,
122 events
p-value
Age (continuous variable) 173/
496
1.10 (1.08–1.11) <0.001 1.10 (1.07–1.12) <0.001
Sex Male vs female (ref) 173/
496
0.93 (0.69–1.25) 0.617 1.35 (0.91–1.99) 0.136
Leukocyte count (continuous variable) 166/
465
�1 (1–1) 0.058 1.01 (0.99–1.03) 0.167
Lymphocyte count (continuous variable) 165/
462
�1 (1–1) 0.077 0.99 (0.97–1.01) 0.227
Morphology SLL vs CLL (ref) 173/
496
1.38 (0.97–1.96) 0.073 1.34 (0.86–2.09) 0.194




2.02 (1.43–2.86) <0.001 1.74 (1.19–2.55) 0.004
B symptoms Present vs absent (ref) 141/
419
0.53 (0.13–0.93) 0.0091 - -
Binet stage 160/
472B vs A (ref) 1.59 (1.07–2.38) 0.023 2.08 (1.30–3.33) 0.002
C vs A (ref) 3.66 (2.37–5.63) <0.001 2.39 (1.36–4.21) 0.002
CCI 173/
4961–2 vs 0 (ref) 1.40 (1.02–1.93) 0.04 1.36 (0.92–2,01) 0.128
3–4 vs 0 (ref) 2.19 (1.28–3.75) 0.004 0.94 (0.49–1.82) 0.858
�5 vs 0 (ref) 3.92 (1.81–8.51) 0.001 2.99 (1.18–7.56) 0.021
CCI, Charlson comorbidities index; CI, confidence interval; CLL, Chronic lymphocytic leukaemia; SLL, Small lymphocytic lymphoma.
1This variable was not included as a covariate because it violated the assumption of proportional hazards.
https://doi.org/10.1371/journal.pone.0258423.t003
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Nevertheless, it should be highlighted that the present work contributed to an accurate CLL/
SLL incidence and survival determination in Portugal and illustrates the importance of adapt-
ing CLL/SLL epidemiologic surveillance to provide reliable and comparable data.
Incidence rates were comparable to other western countries, including the United States of
America (USA), Canada and European countries such as Spain and Sweden, but contrasted with
the incidence in the United Kingdom and Belgium (estimated at 6:100,000 European population)
[29,32–37], which may be related to differences in characteristics of the population and/or risk
factors. Differences were also observed when comparing with data from Eastern Europe, Russia
and Asian countries, where it a lower incidence of this malignancy has been described. Age at
diagnosis and sex ratio were also comparable to other western countries [32,35,37].
The general outcomes of this population, predominantly of early stage CLL and in patients
with good performance status, were very favourable. Median OS was not reached, as could be
expected due to the relatively short follow-up duration in an indolent malignancy (5.46 years).
Nevertheless, the 5-year OS rate is concordant with survival results reported for other devel-
oped countries (mainly western countries such as Germany, Sweden, Norway) and contrasts
with those from developing countries [17,34,37–39].
The analysis of the clinical characteristics at diagnosis showed similarities to data reported
for other developed countries [40–42] and diverges from data from developing countries, in
which patients are diagnosed in more advanced/high risk stages, with higher prevalence of
anaemia and thrombocytopenia [38,42,43]. The proportion of patients with unknown infor-
mation for β2-microglobulin (56.05%) should be noted; although it is independently associ-
ated with OS and response duration [44], it was not systematically evaluated in the study
population. It is also imperative to mention that the majority of patients (53.43%) did not pres-
ent any of the comorbidities of the CCI and had ECOG PS�2. Even though other authors
reported the absence of comorbidities at diagnosis in 70% of CLL patients [45], we recognise
that the application of CCI in CLL is limited. The Cumulative Illness Rating Scale (CIRS), not
available in ROR-Sul database, is more frequently used [46]. Another issue that might have
contributed to these results is the retrospective collection of this information, which could
have led to information bias.
Chromosomal aberrations were evaluated by FISH in 40.93% of patients before treatment,
which represents a limitation for data interpretation. Nonetheless, this proportion of evaluated
patients was expected as, during the study period, the recommendations to conduct this char-
acterisation were still limited and had no impact in therapeutic decisions in our country [47].
Generally, the prevalence of these alterations is in agreement with studies performed in other
populations, although it should be noted the higher proportion of patients without FISH
abnormalities (37.69% vs 15–25%) [17,18,39,43,45]. As mentioned before, this analysis and
interpretation of the results have limitations and, to achieve robust conclusions, more studies
should be performed, ideally prospective, with larger series of patients.
Treatment characterisation showed that a watch and wait strategy was chosen for the
majority of the cases, as recommended in current guidelines and as it would be expected con-
sidering the follow-up duration (5.46 years). First-line treatment options generally agreed with
international recommendations for that time period, although regimens containing anthracy-
clines and vinca alkaloids were also unexpectedly used and should be explored in additional/
future research.
OS stratification per Rai and Binet staging systems, as well as the multivariable analysis,
apparently validate its use in this population (p<0.001 and p = 0.004, respectively). Median OS
was reached for Binet stage C [1.62 years (95%CI 0.63 –not reached)] and Rai stage III/IV
[1.62 years (95%CI 0.64 –not reached)] strata. Although these results differ from others
reported in the literature (e.g. Binet C having a median OS of 7.9 years [17]), the interpretation
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of this data should be cautious due the low number of patients in these stratum (n = 41) and
the short follow-up duration, which contributed to a less precise estimate, as can be appreci-
ated looking at the CI amplitude. Additionally, treatment options, that may have had an
important impact on survival outcomes, were only restrictedly analysed in this series.
Our study confirmed age, lactate dehydrogenase and Binet stage as being independently
associated with OS. In our analysis, a CCI score�5 was independently associated with OS
although CCI 1–4 strata were not. This result is in agreement with those reported in the litera-
ture per other authors [48–50].
Regarding second malignancies, the proportional incidence of CSCC, malignant tumours
of the central nervous system, myelodysplastic syndromes and malignant melanomas of the skin
is superior to that reported to the general population. The SIR observed to any second cancer
identified a 1.59 fold increased risk and this result is concordant with data from other series [51–
53]. Site-specific SIR calculated for CSCC revealed a 10.15 increased risk for the development of
this tumour. There are few studies in the literature that evaluated the risk of developing CSCC
after CLL. Zheng et al. observed a 7.63 fold increased risk (95%CI 7.06–8.25) for the Swedish pop-
ulation and Ishdorj and colleagues found a five-fold increased risk in the Canadian population
[54,55], inferior to our results although with coincident CI. It should be noted that our observa-
tions arise from population-based data, which contributed to cases exhaustiveness of both CLL
and second malignancies and consequently to the accuracy of the estimates. However, we admit
that the number of patients included in this study may have contributed to a less precise estimate
as shown by the CI amplitude. Nevertheless, these results raise concerns and highlight the impor-
tance of adequate clinical watchfulness during the follow-up of CLL patients.
This study has various strengths: it was conducted at the population level, included patients
from both private and public hospital institutions and cases of interest were signalised through
several data sources, which constitute major contributions to the external validity of our
results. It is worth noting the central procedures for data accuracy and validation, which con-
tributed to the internal validity of our work. It is also important to highlight the proportion of
follow-up completeness (99.6%), extremely relevant to characterise the outcomes of interest.
Nonetheless, there are also some limitations, namely the proportion of unknown/not evaluated
information for some of the variables of interest and the absence of some other relevant data
(e.g. autoimmune phenomena), which is inherent to observational/registry studies, but can
lead to information bias. Additionally, it is worth mentioning the possible misclassification
bias of some of the variables of interest used to analyse the outcomes. However, procedures
were implemented to its minimisation, namely the central validation of the information for
those variables. Another limitation concerns the relatively short follow-up considering the
characteristically indolent evolution of this disease; hence, a longer follow-up would be impor-
tant to achieve more robust results.
Conclusions
Our study confirms that epidemiological and clinical characteristics of Portuguese CLL patients
are concordant to those reported from other western countries. Clinical outcomes, measured by
5-year overall survival rates, are also similar to other western countries. The increased risk of
second malignancies raises concerns and needs adequate clinical watchfulness.
Supporting information
S1 Fig. Kaplan-Meier estimate for OS stratified per Rai stage.
(TIF)
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S2 Fig. Kaplan-Meier estimate stratified per Binet stage.
(TIF)
S1 Table. Second malignancies occurred in CLL patients. CLL, Chronic lymphocytic leukae-
mia; CNS, Central nervous system; GIST, Gastrointestinal stromal tumour.
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of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leuk Lymphoma. 2020;
61(3):557–66. https://doi.org/10.1080/10428194.2019.1680840 PMID: 31682164
18. Gade I, Riddersholm S, Christiansen I, Rewes A, Frederiksen M, Enggaard L, et al. Venous thrombo-
embolism in chronic lymphocytic leukemia: a Danish nationwide cohort study. Blood Adv. 2018; 2
(21):3025–34. https://doi.org/10.1182/bloodadvances.2018023895 PMID: 30425066
19. Lenartova A, Johannesen T, Tjønnfjord G. Chronic lymphocytic leukemia and secondary hematological
malignancies: A nation-wide cancer registry study. Eur J Haematol. 2020; 104(6):546–53. https://doi.
org/10.1111/ejh.13396 PMID: 32058605
20. von Elm E, Altman D, Egger M, Pocock S, Gøtzsche P, Vandenbroucke J, et al. The Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. Lancet. 2007; 370(9596):1453–7. https://doi.org/10.1016/S0140-6736(07)
61602-X PMID: 18064739
21. Silva I. Principles and methods: cancer epidemiology. Geneva; 1999.
22. World Health Organization. International Classification of Diseases for Oncology (ICD-O), 3rd Edition
1st revision. 2013.
23. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. https://doi.org/10.
1016/0021-9681(87)90171-8 PMID: 3558716
24. Ferreti S. Airtum cancer registration handbook. 2009.
25. Instituto Nacional de Estatı́stica. Resident population by place of residence (NUTS—2013), sex and
age group, annual, 2013 and 2014.
26. Eurostat. Revision of the European Standard population: report of the Eurostat’s task force. Luxem-
bourg; 2013.
27. Pedersen A, Mikkelsen E, Cronin-Fenton D, Kristensen N, Pham T, Pedersen L, et al. Missing data and
multiple imputation in clinical epidemiological research,” Clinical epidemiology. Clin Epidemiol. 2017;
6:157–66.
28. StataCorp. Stata Statistical Software: Release 13 [Internet]. College Station, TX: StataCorp LP.; 2013.
Available from: https://www.stata.com/.
29. Solans M, Osca-Gelis G, Comas R, Roncero J, Gallardo D, Marcos-Gragera R, et al. Challenges in
assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the
province of Girona, Spain. Cancer Causes Control. 2018; 29(3):379–82. https://doi.org/10.1007/
s10552-018-1004-5 PMID: 29383469
PLOS ONE Epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal
PLOS ONE | https://doi.org/10.1371/journal.pone.0258423 October 8, 2021 12 / 14
30. Seftel MD, Demers AA, Banerji V, Gibson SB, Morales C, Musto G, et al. High incidence of chronic lym-
phocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort.
Leuk Res. 2009; 33(11):1463–8. https://doi.org/10.1016/j.leukres.2009.06.013 PMID: 19581000
31. Olafsson G, Steingrimsdottir H, Vidarson B, Halldorsdottir A. Chronic lymphocytic leukemia in Iceland
from 2003 to 2013: Incidence, presentation and diagnosis. Laeknabladid. 2016; 102(4):171–7. https://
doi.org/10.17992/lbl.2016.04.74 PMID: 27197124
32. The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer institute. Can-
cer fact sheets: chronic lymphocytic leukemia (CLL).
33. Pfeil A, Imfeld P, Pettengell R, Jick S, Szucs T, Meier C, et al. Trends in incidence and medical resource
utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice
Research Datalink (CPRD). Ann Hematol. 2014; 94(3):421–9. https://doi.org/10.1007/s00277-014-
2217-7 PMID: 25219890
34. Mattson M, Sandin F, Kimby E, Hoglund M, Glimelius I. Increasing prevalance of chronic lymphocytic
leukemia with an estimated future rise: A nationwide population-based study. Am J Hematol. 2019;
E36–8. https://doi.org/10.1002/ajh.25681 PMID: 31725930
35. Healey R, Patel J, Koning L, Naugler C. Incidence of chronic lymphocytic leukemia and monoclonal B-
cell lymphocytosis in Calgary, Alberta, Canada. Leuk Res. 2015; 39(4):429–34. https://doi.org/10.1016/
j.leukres.2015.01.015 PMID: 25703352
36. Belgian Cancer Registry. Haematological malignancies in Belgium. Brussels; 2015.
37. Lenartova A, Johanessen T, Tjonnfjord G. National trends in incidence and survival of chronic lympho-
cytic leukemia in Norway for 1953–2012: a systematic analysis of population-based data. Cancer Med.
2016; 5(12):3588–95. https://doi.org/10.1002/cam4.849 PMID: 27925456
38. Hasan K. Clinical Aspects, Immunophenotypic Analysis and Survival Rate of Chronic Lymphocytic Leu-
kaemia Patients in Erbil City, Iraq. Sultan Qaboos Univ Med J. 2018; 18(4):e461–7. https://doi.org/10.
18295/squmj.2018.18.04.006 PMID: 30988964
39. Yan Y, Lv R, Xiong W, Li Z, Wang Y, Yu Y, et al. Subtype Distribution, Clinical Features, and Survival in
B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. Clin Lymphoma, Mye-
loma Leuk. 2019; 20(6):E270–83.
40. Huang S, Gerrie A, Young S, Tucker T, Bruyere H, Hrynchak M, et al. Comparison of real-world treat-
ment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in
the province of British Columbia, Canada. Leuk Res. 2020; 91(106335).
41. Sylvan S, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, et al. First-line therapy in chronic lym-
phocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated
between 2007 and 2013. Haematologica. 2019; 104(4):797–804. https://doi.org/10.3324/haematol.
2018.200204 PMID: 30467205
42. Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, et al.
Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncol-
ogy Latin America Observational Registry Study. J Glob Oncol. 2019;(5):1–19. https://doi.org/10.1200/
JGO.19.00025 PMID: 31774711
43. Tejaswi V, Lad D, Jindal N, Prakash G, Malhotra P, Khadwal A, et al. Chronic Lymphocytic Leukemia:
Real-World Data From India. JCO Glob Oncol. 2020; 6. https://doi.org/10.1200/GO.20.00032 PMID:
32579486
44. International CLL-IPI working group. An international prognostic index for patients with chronic lympho-
cytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779–
90. https://doi.org/10.1016/S1470-2045(16)30029-8 PMID: 27185642
45. Seymour E, Ruterbusch J, Beebe-Dimmer J, Schiffer C. Real-world testing and treatment patterns in
chronic lymphocytic leukemia: A SEER patterns of care analysis. Cancer. 2019; 125(1):135–43. https://
doi.org/10.1002/cncr.31738 PMID: 30343488
46. Linn B, Linn M, Lee G. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16(5):622–6. https://doi.
org/10.1111/j.1532-5415.1968.tb02103.x PMID: 5646906
47. Parikh S, Strati P, Tsang M, West C, Shanafelt T. Should IGHV status and FISH testing be performed in
all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016; 127(14):1752–60.
https://doi.org/10.1182/blood-2015-10-620864 PMID: 26841802
48. Rigolin G, Cavallari M, Quaglia F, Formigaro L, Lista E, Urso A, et al. In CLL, comorbidities and the com-
plex karyotype are associated with an inferior outcome independently of CLL-IPI. Lett to Blood. 2017;
129(26):3495–7. https://doi.org/10.1182/blood-2017-03-772285 PMID: 28446433
49. Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, et al. Interactions between comor-
bidity and treatment of chronic lymphocytic leukemia: Results of German chronic lymphocytic leukemia
PLOS ONE Epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal
PLOS ONE | https://doi.org/10.1371/journal.pone.0258423 October 8, 2021 13 / 14
study group trials. Haematologica. 2014; 99(6):1095–100. https://doi.org/10.3324/haematol.2013.
096792 PMID: 24584349
50. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, et al. Relationship between co-mor-
bidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia
(CLL): a prospective cohort study. Br J Haematol. 2017; 178(3):394–402. https://doi.org/10.1111/bjh.
14785 PMID: 28580636
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